Abstract
Prostaglandins (PGs) are potent autocrine and paracrine oxygenated lipid molecules that contribute appreciably to physiologic and pathophysiologic responses in almost all organs, including brain. Emerging data indicate that the PGs, and more specifically PGE2, play a central role in brain diseases including ischemic injury and several neurodegenerative diseases. Given concerns over the potential toxicity from protracted use of cyclooxygenase inhibitors in the elderly, attention is now focused on blocking PGE2 signaling that is mediated by interactions with four distinct G protein-coupled receptors, EP1-4, which are differentially expressed on neuronal and glial cells throughout the central nervous system. EP1 activation has been shown to mediate Ca2+-dependent neurotoxicity in ischemic injury. EP2 activation has been shown to mediate microglial-induced paracrine neurotoxicity as well as suppress microglia internalization of aggregated neurotoxic peptides. Animal models support the potential efficacy of targeting specific EP receptor subtypes in Alzheimers disease, Parkinsons disease, amyotrophic lateral sclerosis, and ischemic stroke. However promising these preclinical studies are, they have yet to be followed by clinical trials targeting any EP receptor in neurologic diseases.
Keywords: Prostaglandins, PGE2, CNS, neurodegeneration, EP receptors
Current Medicinal Chemistry
Title: Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Volume: 15 Issue: 19
Author(s): P. J. Cimino, C. Dirk Keene, Richard M. Breyer, Kathleen S. Montine and Thomas J. Montine
Affiliation:
Keywords: Prostaglandins, PGE2, CNS, neurodegeneration, EP receptors
Abstract: Prostaglandins (PGs) are potent autocrine and paracrine oxygenated lipid molecules that contribute appreciably to physiologic and pathophysiologic responses in almost all organs, including brain. Emerging data indicate that the PGs, and more specifically PGE2, play a central role in brain diseases including ischemic injury and several neurodegenerative diseases. Given concerns over the potential toxicity from protracted use of cyclooxygenase inhibitors in the elderly, attention is now focused on blocking PGE2 signaling that is mediated by interactions with four distinct G protein-coupled receptors, EP1-4, which are differentially expressed on neuronal and glial cells throughout the central nervous system. EP1 activation has been shown to mediate Ca2+-dependent neurotoxicity in ischemic injury. EP2 activation has been shown to mediate microglial-induced paracrine neurotoxicity as well as suppress microglia internalization of aggregated neurotoxic peptides. Animal models support the potential efficacy of targeting specific EP receptor subtypes in Alzheimers disease, Parkinsons disease, amyotrophic lateral sclerosis, and ischemic stroke. However promising these preclinical studies are, they have yet to be followed by clinical trials targeting any EP receptor in neurologic diseases.
Export Options
About this article
Cite this article as:
Cimino J. P., Keene Dirk C., Breyer M. Richard, Montine S. Kathleen and Montine J. Thomas, Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease, Current Medicinal Chemistry 2008; 15 (19) . https://dx.doi.org/10.2174/092986708785132915
DOI https://dx.doi.org/10.2174/092986708785132915 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Attenuating Muscle Wasting: Cell and Gene Therapy Approaches
Current Genomics Anti-Inflammatory Therapy for Alzheimer’s Disease from Epidemiological Fact to New Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Solvent-Free Synthesis of 4,5-Dihydropyrano[c]chromene Derivatives Over TiO<sub>2</sub> Nanoparticles as an Economical and Efficient Catalyst
Current Catalysis Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Biological and Pharmacological Effects of Gamma-oryzanol: An Updated Review of the Molecular Mechanisms
Current Pharmaceutical Design A Comprehensive Review on Recent advances in Synthesis & Pharmacotherapeutic potential of Benzothiazoles
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design Cation-Responsive MRI Contrast Agents Based on Gadolinium(III)
Current Inorganic Chemistry (Discontinued) The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Population Studies of Association Between Lithium and Risk of Neurodegenerative Disorders
Current Alzheimer Research Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy
Current Genomics Inhibitors of Myostatin- and Proteasome-Dependent Signaling for Attenuating Muscle Wasting
Recent Patents on Regenerative Medicine Neurotoxicity of Insecticides
Current Medicinal Chemistry Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research